ProCE Banner Activity

How I Use BTK Inhibitors to Treat Patients With MCL and MZL

Clinical Thought
Gain insights for treating patients with mantle cell or marginal zone lymphomas with BTK inhibitors in this expert commentary.

Released: March 03, 2020

Expiration: March 02, 2021

No longer available for credit.

Share

Faculty

Farrukh Awan

Farrukh Awan, MD, MS

Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pharmacyclics AbbVie

Faculty Disclosure

Primary Author

Farrukh Awan, MD, MS

Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Farrukh Awan, MD, MS, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, Blueprint, Celgene, Dava Oncology, Genentech, Gilead Sciences, Janssen, Karyopharm, Kite Pharma, MEI Pharma, Pharmacyclics, and Sunesis